260 results on '"Mekhail T"'
Search Results
2. EP03.01-02 Molecular Characterization of Non-small Cell Lung Cancer in People Living with HIV or Solid Organ Transplants
3. 988P Phase I/II study of mobocertinib in EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): Updated results from platinum-pretreated patients (PPP)
4. EP08.02-171 PRO-CTCAE Analysis of Mobocertinib in EGFR Exon 20 Insertion‒Positive Metastatic Non‒Small Cell Lung Cancer (NSCLC)
5. 120O Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind study
6. FP09.01 Mobocertinib in Platinum-Pretreated EGFR Exon 20 Insertion+ Metastatic NSCLC Patients With/Without Prior Anti-PD(L)-1 Therapy
7. OA15.01 Mobocertinib in EGFR Exon 20 Insertion–Positive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy
8. FP09.02 Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes From EXCLAIM Extension Cohort
9. 643TiP Open-label, phase II study of ladiratuzumab vedotin (LV) for unresectable locally advanced or metastatic solid tumors
10. 1231P Characterization and management of mobocertinib (TAK-788) induced skin toxicity in patients with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) who previously received platinum chemotherapy
11. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib
12. Phase Ι trial of weekly Docetaxel and daily Temozolomide in patients with metastatic disease
13. A Rare Case of Primary Cardiac Lymphoma with Extensive Myocardial Invasion And High-Grade Right Ventricular Outflow Tract Obstruction Demonstrating a Complete Metabolic Response to Chemotherapy
14. OA04.03 Mobocertinib in NSCLC With EGFR Exon 20 Insertions: Results From EXCLAIM and Pooled Platinum-Pretreated Patient Populations
15. Phase I trial of three-weekly Docetaxel, Carboplatin and oral lenalidomide (Revlimid®) in patients with advanced solid tumors
16. Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer
17. 1261MO Updated results from a phase I/II study of mobocertinib (TAK-788) in NSCLC with EGFR exon 20 insertions (exon20ins)
18. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
19. Phase I trial of weekly Docetaxel and daily Temozolomide in patients with metastatic disease
20. Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma
21. P1.01-112 Phase 3, Randomized, Double-Blind Trial of First-Line Pembrolizumab With or Without Lenvatinib in Metastatic NSCLC: LEAP-007
22. P2.01-14 Phase 3 Trial of Sitravatinib Plus Nivolumab vs Docetaxel for Treatment of NSCLC After Platinum-Based Chemoimmunotherapy
23. EP1.12-06 New Treatment Option for ES-SCLC: Patient Characteristics and Use of an Atezolizumab Regimen in the Real-World Setting
24. Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)
25. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
26. PL02.01 Overall Survival with Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC
27. Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)
28. IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC
29. PACIFIC: A Double-Blind, Placebo-Controlled Phase 3 Study of Durvalumab as Consolidation Therapy After Chemoradiation in Patients with Locally Advanced, Unresectable Non–Small Cell Lung Cancer
30. MA 15.02 Plasma CfDNA next Generation Sequencing in Non-Small Cell Lung Cancer: Clinical Outcomes and Comparison to Tissue
31. PACIFIC: A double-blind, placebo-controlled Phase III study of durvalumab as consolidation therapy after chemoradiation in patients with locally advanced, unresectable NSCLC
32. Overall survival (OS) for first-line crizotinib versus chemotherapy in ALK+ lung cancer: Updated results from PROFILE 1014
33. PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC
34. LBA83 - Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)
35. LBA55 - Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)
36. LBA53 - IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC
37. 3009 Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement
38. 3101 Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC)
39. 403O - PACIFIC: A double-blind, placebo-controlled Phase III study of durvalumab as consolidation therapy after chemoradiation in patients with locally advanced, unresectable NSCLC
40. LBA1_PR - PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC
41. LBA50 - Overall survival (OS) for first-line crizotinib versus chemotherapy in ALK+ lung cancer: Updated results from PROFILE 1014
42. 10LBA Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer
43. Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC): Results From a Phase 2, Placebo-Controlled Study (GO27821)
44. Overall and Intracranial (Ic) Efficacy Results and Time to Symptom Deterioration in Profile 1014: 1St-Line Crizotinib Vs Pemetrexed - Platinum Chemotherapy (Ppc) in Patients (Pts) with Advanced Alk-Positive Non-Squamous Non-Small Cell Lung Cancer (Nsclc)
45. Impact of Crizotinib on Patient-Reported Symptoms and Global Quality of Life (Qol) Compared with Platinum Based Chemotherapy in Phase III Study of Treatment Naïve Advanced Alk-Positive Non-Small Cell Lung Cancer (Nsclc)
46. Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR TKI-responsive, advanced non-small cell lung cancer (NSCLC) that subsequently progresses.
47. Clinical predictors of prolonged clinical benefit (PCB) from pemetrexed (P) therapy in metastatic non-small cell lung cancer (mNSCLC).
48. Pleural Mesothelioma Treated with Induction Platinum Based Chemotherapy followed by Extrapleural Pneumonectomy and Adjuvant Intensity-modulated Radiation Therapy: The Cleveland Clinic Experience
49. Phase I/II Trial of the Addition of Erlotinib to Pre- and Postoperative Chemotherapy/Hyperfractionated Radiotherapy, and as Maintenance, for Resectable Mediastinoscopy-defined Stage III Non–small-cell Lung Cancer (NSCLC): Report on the Phase II Component
50. Final results: A dose escalation phase I study of ARQ 197, a selective c-Met inhibitor, in patients with metastatic solid tumors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.